Femasys (NASDAQ: FEMY) director awarded 34,122 Series D-1 warrants

Rhea-AI Filing Summary

Femasys Inc. director Charles Larsen received a grant of 34,122 Series D-1 Warrants to acquire common stock. The warrants were issued in a private placement as consideration under an Omnibus Amendment and Consent Agreement dated March 19, 2026. Each warrant has an initial exercise price of $0.58 per share of common stock and is subject to anti-dilution adjustments for events such as stock splits or stock dividends. The holder’s ability to exercise the warrants is limited by Nasdaq Capital Market rules. The warrants are exercisable into 34,122 shares of common stock and expire on March 19, 2036, leaving Larsen holding 34,122 Series D-1 Warrants after this grant.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Larsen Charles

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Series D-1 Warrants	34,122	$0.00	--

Holdings After Transaction: Series D-1 Warrants — 34,122 shares (Direct)

Footnotes (1)

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Larsen Charles

(Last) (First) (Middle)

C/O FEMASYS INC.

3950 JOHNS CREEK COURT, SUITE 100

(Street)

SUWANEE GEORGIA 30024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FEMASYS INC [ FEMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series D-1 Warrants	$0.58(1)	03/19/2026		A		34,122		03/19/2026	03/19/2036	Common stock, par value $0.001 per share	34,122(2)	(3)	34,122	D

Explanation of Responses:

1. Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

2. The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

3. The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

	/s/ Kathy Lee-Sepsick, Attorney-in-fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Femasys (FEMY) report for Charles Larsen?

Femasys reported that director Charles Larsen received 34,122 Series D-1 Warrants as a grant. These derivative securities allow him to acquire common stock and were issued as consideration in a private placement tied to an Omnibus Amendment and Consent Agreement dated March 19, 2026.

What are the key terms of the Femasys Series D-1 Warrants granted to Charles Larsen?

The Series D-1 Warrants granted to Charles Larsen cover 34,122 underlying common shares at an initial exercise price of $0.58 per share. The exercise price is adjustable for stock splits, stock dividends, combinations, recapitalizations, and similar corporate actions, and the warrants expire on March 19, 2036.

How many Femasys Series D-1 Warrants does Charles Larsen hold after this Form 4?

After this transaction, Charles Larsen holds 34,122 Series D-1 Warrants directly. Each warrant is exercisable for one share of Femasys common stock, so the position represents 34,122 underlying common shares, subject to exercise limitations and any future warrant adjustments.

What limits apply to exercising the Femasys Series D-1 Warrants reported on this Form 4?

The holder’s ability to exercise the Series D-1 Warrants for Femasys common stock is subject to certain limitations under Nasdaq Capital Market rules. These constraints govern how and when the warrants can be exercised, even though they are otherwise exercisable at $0.58 per share until March 19, 2036.

Why were the Femasys Series D-1 Warrants issued to Charles Larsen at no cost?

The warrants were issued to Charles Larsen as consideration in a private placement, connected to an Omnibus Amendment and Consent Agreement dated March 19, 2026. As a result, the Form 4 shows 34,122 Series D-1 Warrants acquired at a transaction price of $0.00 per warrant.